Healthcare Industry News: periodontal disease
News Release - August 20, 2008
PathoLase, Inc. Appoints Skip Phairas as Chief Operating Officer
Experienced veteran to lead Company through high growth phaseCHICO, Calif.--(HSMN NewsFeed)--PathoLase, Inc., an emerging leader in the medical technology industry, announced today that it has appointed Skip Phairas as its first Chief Operating Officer. With over 35 years of experience, he brings a wide variety of skills and experience from the high technology industry including executive positions with Fortune 500 companies, regional firms and high tech start-ups. After working with the Company on a consulting basis, Phairas assumes his new position immediately.
“Skip brings a tremendous set of skills and experience to PathoLase as we set out to build a national market for our innovative laser technology,” said John Strisower, founder and CEO. “As the only medical technology company presently in the marketplace with this remarkable technology, we’ve set aggressive goals for acquiring national market share quickly. We believe we can legitimately become a $1B company in the next few years – with strengths in business development, sales and marketing, Skip has the experience to build the infrastructure we will need to support that goal and the ability to manage it as we rapidly scale toward it.”
“I’m delighted to join the company at this point in its growth curve,” said Phairas. “As a platform technology company, PathoLase has a tremendous opportunity to bring a number of next generation laser solutions to the marketplace. Having built high performance teams before, I look forward to building the caliber of executive management team and national field organization needed to manage the rapid growth we expect as we enter the US market.”
PathoLase introduced its patented laser technology that kills the pathogens that cause toenail fungus at the annual American Podiatric Medical Association scientific meeting last month in Hawaii. Interest has developed swiftly from within the podiatric community as PathoLase is now in discussions with leading podiatrists in over 20 major metropolitan markets within the US.
About PathoLase
Founded in 2004, PathoLase, Inc. is a privately held emerging medical technology company with headquarters in Northern California. PathoLase has assembled a world-class group of top scientists, academic thought leaders and leading practitioners from around the US and Canada to develop and bring to market a new generation of laser technology solutions that address a series of medical issues, from toenail fungus and periodontal disease to more serious life threatening problems, such as blood borne and respiratory infections.
PathoLase’s first laser solution now going to market addresses the pathogens that cause toenail fungus (Onychomycosis), an infection that afflicts an estimated 35 million people in the US alone. With $6M of private equity capital recently secured from Nexus Medical Partners, PathoLase is rapidly placing its patented technology in the hands of leading podiatrists around the country.
Source: PathoLase
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
